eLearning

eLearning Program

Chronic Spontaneous Urticaria: Diagnosis and Treatment in Primary Care

Dr Werner J Barnard — Length: 08:02

This eXtract video features key information on the practical implementation of the recommended treatment algorithm for Chronic Spontaneous Urticaria (CSU), also known as chronic idiopathic urticaria. CSU is not a life-threatening condition but can impose meaningful reduction in quality of life even when present in mild to moderate severity.

eLearning Program

DECLARE-TIMI 58 Subanalysis Expands Evidence of CV Benefits

Dr Lawrence Leiter — Length: 08:19

This eXtract video features key information from the American College of Cardiology (ACC) Scientific Sessions & Expo. This quick tour with an expert focuses on data presented on the sub-analysis of the DECLARE-TIMI 58 trial, the most recent cardiovascular outcome trial (CVOT) conducted with sodium glucose co-transporter-2 (SGLT2) inhibitors.

eLearning Program

Optimizing In-Hospital and Postdischarge Chronic Heart Failure Therapies

Dr. Rolf Wachter — Length: 09:51

This eXtract video features key information from the American Heart Association (AHA) Scientific Sessions. This quick tour with an expert focuses on data presented on the optimization of chronic heart failure therapies in-hospital and in the postdischarge phase with an emphasis on the PIONEER-HF and TRANSITION trials.

eLearning Program

HAWK and HARRIER Trials Reaffirm Direction for a Novel Anti-VEGF

Dr. Pravin U. Dugel — Length: 10:50

This eXtract video features key information from the American Academy of Ophthalmology (AAO) Annual Meeting. This quick tour with an expert focuses on data presented on Phase 3 studies (HAWK and HARRIER) which reaffirms the future role of this novel anti-VEGF therapy in the management of neovascular age-related macular degeneration (nAMD) in Canada.

eLearning Program

New Recommendations Reconfirm Bronchodilators as Cornerstone of COPD Treatment

Dr. Charles K.N. Chan — Length: 26:33

Chronic obstructive pulmonary disease (COPD) is a disease that is typically progressive, and not fully reversible, with chronic and continuous respiratory symptoms. The GOLD guidelines recommend LAMAs, LABAs and their combination as the cornerstone of therapy for GOLD B, C and D patients. Many LABA/LAMA combinations have been studied in COPD; however, not all of them have demonstrated the same benefits. This program will review the recommendations for dual therapy and the evidence supporting these recommendations.

eLearning Program

More than just Red Blood cells, Polycythaemia Vera is a Cancer

Dr. Nicholas Finn — Length: 26:35

Polycythaemia vera (PV) is a myeloproliferative neoplasm (MPN), a type of progressive blood cancer. Patients diagnosed with PV have a characteristic over-proliferation of not only red blood cells, but also of white blood cells and platelets. The symptoms of PV are driven by a number of underlying mechanisms. Therapy to adequately control these mechanisms is key to relieving PV patients from their burdensome symptoms and disease-related complications. Therapies are available to manage blood counts and minimize the risk of complications, even in patients who are intolerant or resistant to conventional therapies. This program will review PV, its diagnosis and available treatment options.

eLearning Program

Triple Therapy in COPD: Who and Why?

Dr. Shawn Aaron — Length: 26:39

Chronic obstructive pulmonary disease (COPD) is a disease that is typically progressive, and not fully reversible, with chronic and continuous respiratory symptoms. COPD is responsible for approximately 3 million deaths annually. The GOLD guidelines recommend a LAMA + LABA combination as initial therapy in patients with advanced disease (i.e., a predicted FEV1 of <30%). Triple therapy – a LAMA + LABA + an inhaled corticosteroid (ICS) – is recommended in patients who experience further exacerbation(s) on a LAMA + LABA combination. This program will review the recommendations for triple therapy and the evidence supporting these recommendations.

eLearning Program

Refractory Multiple Myeloma: The Shifting Treatment Paradigm

Dr. Donna E. Reece — Length: 23:32

There has been a recent and important expansion in the treatment options for relapsed and refractory multiple myeloma. These options, which included new drugs from existing therapeutic classes and novel agents that have introduced unique mechanisms of action, provide an opportunity to extend disease control with a good quality of life. In this program, new treatment options for advanced multiple myeloma are explored with attention to the rationale for individualizing treatments to prolong survival.

eLearning Program

Familial Hypercholesterolemia: Preventing Cardiovascular Events

Dr. Robert A. Hegele — Length: 34:37

Based on current estimates, more than 85,000 Canadians have familial hypercholesterolemia, most of whom remain undiagnosed. This condition dramatically accelerates the development of atherosclerosis, driving an accelerated rate of cardiovascular disease, including about an 8-fold increase in risk of cardiovascular death in individuals between the ages of 20 and 50 years. The introduction of PCSK9 inhibitors has provided an opportunity to normalize the lifespan of these individuals.

This web site is solely for healthcare professionals

Yes, I am a healthcare professional No, I am not a healthcare professional